Cybrexa Therapeutics Appoints Keely Zipp as Vice President of Marketing
Adds oncology marketing and strategy experience from Incyte Corporation and GlaxoSmithKline
New Haven, Conn., October 8, 2018 – Cybrexa Therapeutics, an early-stage biotechnology company developing a new class of cancer therapeutics through its tumor-selective technology platform, today announced that it further strengthened its leadership team with the appointment of Keely Zipp as Vice President of Marketing. Ms. Zipp adds nearly 15 years of strategic planning and marketing experience to the Cybrexa team and will lead the company’s marketing, communications, and branding efforts.
Ms. Zipp brings with her a breadth of knowledge in business development, corporate operations, and strategic marketing. Prior to joining Cybrexa, she served as Senior Director of Global Strategic Planning and Corporate Operations at Incyte Corporation (NASDAQ: INCY) where she led corporate and product strategy and financial planning initiatives for the publicly-traded, commercial-stage, biotechnology company. Previously, Ms. Zipp served as Commercial Director at GlaxoSmithKline (NYSE: GSK), where she developed, implemented, and embedded business strategies, processes, and change initiatives across the Global Oncology Franchise. She was also a Manager of Global Business Development, Mergers & Acquisitions at Wyeth, a Pfizer company. Ms. Zipp holds an MBA from The Wharton School at the University of Pennsylvania and graduated magna cum laude with a BA in Biochemistry and Molecular Biology from Dartmouth College.
"I am confident that Keely’s depth of experience working at large, commercial stage companies will prove invaluable as Cybrexa advances its lead candidate into the clinic," said Per Hellsund, President and Chief Executive Officer of Cybrexa Therapeutics. "In addition to Keely’s impressive experience within the life sciences arena, she also exemplifies our core values, and we are delighted to welcome her to the Cybrexa team."
Keely Zipp, VP of Marketing at Cybrexa, added, “I am delighted to join Cybrexa as the team further positions the Company for clinical success and corporate growth, while working to provide such a meaningful platform that has the potential to impact so many lives. Cybrexa represents a unique opportunity as an early-stage oncology company with a truly innovative tumor-selective technology platform and I look forward to working diligently with the team to execute on its corporate objectives.”
Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors and DNA damaging agents (TSDs) that directly target the tumor microenvironment. This approach will both improve the efficacy while at the same time reduce toxicity of existing cancer drugs. The Company has made significant progress since its inception and now has several drug candidates that are being run through its in vitro and in vivo screening platform. The objective is to have at least one of its TSDs ready for a phase I clinical trial within two years. Cybrexa was founded by successful entrepreneurs Per Hellsund, Kevin Didden and Kevin Rakin, who most recently built and successfully exited Cyvek, Inc. For more information about Cybrexa, please visit www.cybrexa.com.